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Background: Stable human cell lines have gradually become the preferred system for large scale production of
recombinant proteins for clinical applications because of their capacity of proper protein post-translational
modification and low immunogenicity. However, human cell line development technologies are commonly based
on random genome integration of protein expressing genes. It is required to screen large numbers of cell clones to
identify stable high producer cell clones and the cell line development process usually takes 6 to 12 months.
Adeno-associated virus type 2 (AAV2) Rep protein is known to induce rAAV DNA integration into a specific site
(AAVS1) of the human chromosome 19 and integrated transgenes can stably express proteins. We take advantage
of this AAV unique feature to develop a rapid protocol to clone a stable recombinant protein expression human
cell line.
Findings: We have constructed two plasmids. One plasmid, pSVAV2, contains the AAV rep gene for the synthesis of
integrase; the second plasmid, pTRP5GFPFVIII-BDD, contains B-domain-deleted factor VIII (FVIII-BDD) and GFP gene
flanked by AAV ITRs. Human embryonic kidney (HEK) 293 cells were co-transfected with the two plasmids and the
cells were screened by green fluorescence to establish the recombinant FVIII-BDD cell line. PCR analysis showed
that the FVIII-BDD gene has been integrated into the AAVS1 site of human chromosome 19. The FVIII-BDD protein
secreted into the extracellular media exhibited coagulant activity.
Conclusion: We developed a method of rapid establishment of human HEK 293 cell line expressing recombinant
FVIII-BDD protein with AAV site-specific integration plasmids.
Keywords: B-domain-deleted FVIII (FVIII-BDD), Site-specific integration, HEK 293 cell line, Adeno-associated
virus (AAV)Findings
Introduction
In recent years, the number of recombinant proteins
used for therapeutic applications has increased dramatic-
ally. Stable human cell lines have been extensively used
as a preferred expression system for recombinant pro-
teins because their biochemical machineries are capable
of carrying out most of the post-translational folding
and processing required for generating functional and
mature protein and provide high protein productivity* Correspondence: chunzhang@sibet.ac.cn
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unless otherwise stated.[1]. While traditional stable transfection strategies typic-
ally involve the random integration of foreign genes into
chromosomes, it is difficult to obtain homogenous level
of protein expression among individual transfected cells,
and the gene amplification process results in large gen-
omic rearrangements that lead to further heterogeneity
in protein expression levels. Furthermore, the produc-
tion cell line development process typically requires 6 to
12 months [2]. Site specific integration of protein ex-
pressing genes offers an alternative strategy to develop
high producing and stable clones in a predictable man-
ner [3]. This greatly improves the recombination effi-
ciency through the use of recombinases, in contrast to
the traditional homologous recombination.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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eukaryotic virus which has the capability of undergoing
site-specific integration into the human genome. Wild-type
(wt) viral DNA recombines at chromosome (ch) -19.13.3
qter at a frequency of 70% [4,5]. Some elements have
been involved in site-specific integration: the AAV
Rep68/78 protein in trans as recombinase [6], and the
AAV inverted terminal repeat (ITR) in cis (this may
not be essential if the P5 promoter, which contains a
Rep-binding site [RBS], is present), and AAVS1, a unique
sequence in the human genome [5,7-9]. Rep-dependent
integration of ITR-flanked cassettes has been reported in
human primary cells and human cell lines. The majority
of integrations were site specific and occurred within a
1000-bp region of AAVS1 [10].
Hemophilia A or factor VIII deficiency is a common
X-linked genetic bleeding disorder in humans, occurring
in about 10-20 males per million [11]. Recombinant
FVIII (rhFVIII) products have been available for 20
years; so far, all are produced in non-human cell lines,
which produce recombinant proteins with a non-human
pattern of post-translational modifications (PTMs) [12].
Recently, human cell lines have been used to produce
rhFVIII and represent an improvement in the category
of rhFVIII production [12-15]. Both the avoidance of
non-human glycan structures and the achievement of
complete sulfation are proposed to lessen the intrinsic
immunogenicity of human-derived rhFVIII compared
with current rFVIII products.
In this study, we have constructed two plasmids. One
plasmid, pSVAV2, contains the AAV rep gene expressing
Rep protein which functions as integrase; another plas-
mid, pTRP5GFPFVIII-BDD, contains B-domain-deleted
FVIII (FVIII-BDD) and GFP gene flanked by AAV ITRs.
AAV ITRs contains cis elements recognized by Rep pro-
tein and guides the site specific integration event. Human
embryonic kidney (HEK) 293 cells were co-transfected
with the two plasmids and resulted cells were screened
by green fluorescence to establish the recombinant
FVIII-BDD cell line. The cell line produced active FVIII-
BDD that was secreted into the cultured media. The cell
line development process took 3 months.
Materials and methods
Construction of the recombinant cell line
Standard procedures were followed for plasmid construc-
tion, growth, and purification. The plasmid pZp9FVIII△BS
containing the B-domain deleted FVIII-BDD cDNA was
used as the template for polymerase chain reaction (PCR)
(a gift from Prof. Cheng-Wu Chi, Shanghai Institute of
Biochemistry, Academia Sinica, Shanghai, China). pTR-
P5GDNFGFP and pSVAV2 were kindly provided by Dr.
Berns, University of Florida, US. The GDNF gene of
the plasmid pTRP5GDNFGFP was replaced with FVIII-BDD gene and the resultant plasmid was named as
pTRP5GFPFVIII-BDD.
The human embryonic kidney 293 cell line was obtained
from the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China). Monolayer cultures of HEK 293 cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Hyclone, USA) supplemented with 10% fetal
bovine serum (Gibco, USA) and 1% penicillin and strepto-
mycin (Beyotime, China). HEK 293 cells (1 × 105) were
seeded in 24-well plates and co-transfected with
pTRP5GFPFVIII-BDD and pSVAV2 at ratio of 50: 1 using
Polyethylenimine (PEI) according to the manufacturer’s
instructions. 25 kDa linear PEI, were purchased from Poly-
science (Warrington, PA), and used to prepare a stock 50
mM solution. Then we set up two tubes with either 1 μL
of pTRP5GFPFVIII-BDD and 20 ng of pSVAV2, or 0.9 μL
of PEI, added 50 μL of HBS (20 mM Hepes buffer, pH 7.4,
150 mM NaCl) to each and incubated them at room
temperature for 10 min. The two dilutions were then
mixed together and incubated at room temperature for an
additional 10 min to allow the formation of PEI-DNA
complexes. The reaction mixture was added to the mono-
layers. After 3 days of transfection, cells were subcultured
twice by diluting 1:3. Cells were cloned as follows: cells
were plated at 10 cells per well into 96-well plates. Two
weeks later, wells containing cells expressing green fluor-
escence were identified and expanded into a 24-well plate,
grown for 5 days, and subsequently cloned into 96-well
plate at one cell per well, and the above process was re-
peated. The single cell cloned fluorescence-positive cell
clones were enlarged. The percentage of GFP-positive cells
of a selected clone was examined by flow cytometric ana-
lysis (FACS, BD LSRFortessa™).
PCR analysis of the site-specific integration of FVIII-BDD
gene
Total genomic DNA was isolated from GFP expression
HEK 293 cells. The transgenes were examined by PCR per-
formed with FVIII primers (sense primer: 5′-CATCGCTA
GCGCCACCATGCAAATAGAGCTC, anti-sense primer:
5′-GCAGAACCAATGCATTCAGTAGAGGTCCTG), and
GFP primers (sense primer: 5′- AGGGGGAGGTGTGG
GAGGTTTT, anti-sense primer: 5′- CCCAGCAGCGGT
CACAAACT), respectively. The site-specific integration
was confirmed with AAV D-sequence sense primer
HAIJP1 (5′-AGGAACCCCTAGTGATGGAG) and a hu-
man chromosome 19 AAVS1 -specific anti-sense primer
HAIJP2 (5′-TCAGAGGACATCACGTGGTG) [16].
FVIII-BDD expression analysis
Total RNA was extracted from recombinant FVIII-BDD
cell line using Trizol Reagent (Sigma, USA) following the
manufacturer's instructions. RNA (500ng) was reverse
transcribed to cDNA with oligo (dT) primer according to
Figure 1 (See legend on next page.)
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Figure 1 Illustration of a typical process to develop site-specific integration of transgene expressing human cell lines. In this process,
two plasmids are essential. One plasmid contains the gene of interest and GFP gene with associated regulatory elements flanked by two copies
of the AAV ITR. This construct contains the cis-acting IEE sequence from the P5 promoter, which is required for optimal site-specific integration.
Another plasmid contains AAV rep gene providing an integration enzyme. HEK 293 cells were co-transfected with the two plasmids at ratio of 50:
1 using PEI. Transfected cells are subcloned into 96-well plates three times and screened by green fluorescence to establish the GFP expression
human cell lines. The fluorescence-positive single cell clones were chosen for progressive expansions and further clone evaluations.
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Kit (Thermo, USA). Real-time PCR assay was applied to
determine the expression of FVIII-BDD with cDNA (1 μL
cDNA diluted 1:10). Gene expression of FVIII-BDD was
quantified using the SYBR Green PCR Master Mix kit
(Tiangen, Beijing) and FVIII specific primers (sense
primer: 5′ TGATGATGACAACTCTCCTT, anti-sense
primer: 5′ TCTTCAGCAGCAATGTAATG) on the 7500
Real-Time PCR System (Applied Biosystems). Cycling was
carried out for 2 min at 50°C, followed by denaturation at
95°C for 10 min. Amplification was carried out with 40
cycles of 95°C for 15 s and at 60°C for 1min. The specifi-
city of each primer pair was confirmed by melting curve
analysis. The GAPDH gene was used as an endogenous
control (housekeeping gene). All reactions were carried
out in triplicate, and the relative expression levels were
calculated using the comparative CT method with the
mean of the virgin cells used as reference [17].
The cloned cells were cultured on T-25 flask; the
media was changed to serum-free media when theyFigure 2 GFP expression of a selected stable cell clone of pTRP5GFPF
picture of the pTRP5GFPFVIII-BDD transduced stable HEK 293 cell line. Scale
expression of a selected stable cell clone of pTRP5GFPFVIII-BDD transduced
line, showing that 99.9% were GFP positive.reached a confluence of above 90%. Following cultured
in serum-free media for 48h, media were collected and
the total proteins in media were concentrated by using
Amicon® Ultra-4 Centrifugal Filter Devices (Millipore,
USA) and resolved on 8% SDS-PAGE, and probed with
Factor VIII (S2194) pAb (Bioword, USA). Unbound anti-
bodies were washed from the blots with Tris-Tween
buffered saline (TBST) solution and subsequently the
membrane was incubated with an alkaline phosphatase-
conjugated polyclonal goat anti-rabbit secondary anti-
bodies (Abgent, USA) at 1: 5,000 dilution. After removing
the secondary antibodies with wash buffer, blots were
treated with chemiluminescent substrate (Millipore, USA).
The blot was then exposed to X-ray film. Untransfected
cells following the same experimental procedure were
used as negative controls.
Procoagulant activity assay of FVIII-BDD
FVIII-BDD protein activity was measured by the
chromogenic-based method using the Coamatic factorVIII-BDD transduced HEK 293 cell. A). Green fluorescent microscope
bar corresponds to 10 μm. B). Flow cytometric analysis of GFP
HEK 293 cell. (a) Negative HEK 293 cell; (b) The cloned HEK 293 cell
Figure 3 PCR analysis of transgene in the cloned cell line
genome. Lane 1. FVIII-BDD gene; Lane 2. GFP gene; Lane 3. AAVS1
site-specific integration, the red arrow indicated the product from
junction PCR (amplification with AAV D-sequence primer and an
AAVS1-specific primer); Lane 4. Negative control.
Figure 4 FVIII-BDD protein expression in the cloned cell lines.
The total proteins in the cultured serum-free media of cloned cells
were concentrated to identify the expression of FVIII-BDD proteins,
and probed with Factor VIII (S2194) pAb. Lane 1. HEK 293-FVIII-BDD
cells; Lane 2. Mock HEK 293 cells.
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instructions. The cloned cells were cultured in 24-well
plate; serum-free and phenol red free DMEM medium
was used when they reached a confluence of about 80%.
After cultured at 37°C for 72 hours, the conditioned media
was collected to measure the procoagulant activity of
FVIII-BDD. The standard curve 0-1 IU/mL was prepared
using a recombinant coagulation factor VIII (Bayer,
Germany), and HEK 293 cells were used as the control.
Results
For the site specific integration of AAV into human
chromosome 19, we used two plasmids, a Rep expression
plasmid and a transgene integration plasmid. The trans-
gene integration vector pTRP5GFPFVIII-BDD contains
the FVIII-BDD gene, which is driven by the cytomegalo-
virus (CMV) enhancer and chicken β-actin (CBA) pro-
moter, and the GFP gene expression were driven by the
herpes simplex thymidine kinase promoter. Gene cas-
settes were flanked between AAV ITRs. The AAV ITR
contains cis-acting IEE sequence from the P5 promoter,
which is required for optimal site-specific integration
(Figure 1). Human embryonic kidney (HEK) 293 cells
were co-transfected with the two plasmids and screened
by green fluorescence. After 3 days of transfection, cells
were subcultured twice. When the cells divided, the vec-
tors unintegrated were diluted out. Followed by 3 times
of single cell cloning, six GFP-expression cell clones were
obtained (Figure 2A). Flow cytometric analysis indicated
that the percentage of GFP-positive cells of a selected
clone was 99.9% (Figure 2B).
PCR analysis was employed to detect whether FVIII-
BDD gene has been integrated into the AAVS1 site of
the GFP-expression cells. First, the FVIII-BDD primers
and GFP primers were used to test the complete integra-
tion of the FVIII-BDD gene.
The results showed a 4.4 kb product indicating the full
length of FVIII-BDD gene (Figure 3, lane 1) and a 1 kb
product indicating partial of GFP gene cassette (Figure 3,
lane 2). The subsequent sequencing analysis demon-
strated that the FVIII-BDD gene has no mutation. Then,
we used junction PCR assay to further investigate
whether the FVIII-BDD integrated at AAVS1 site or not.
A rAAV sense-primer, HAIJP1, and an AAVS1 anti-
sense-primer, HAIJP2, were used to carry out the PCR
(Figure 3, lane 3). The results indicated that FVIII-BDD
gene was integrated into AAVS1 site of chromosome 19.
The FVIII-BDD site specific integrated HEK 293 cell line
was established and named as HEK 293-FVIII-BDD.
We compared the expression levels of FVIII-BDD and
GFP mRNAs in HEK 293-FVIII-BDD and virgin HEK
293 cells. The real-time PCR results showed that in HEK
293-FVIII-BDD cells, the amount of FVIII-BDD and
GFP mRNAs were 2,236- and 3,043- fold higher thanthat in virgin cells. The recombinant FVIII-BDD protein
in the HEK 293-FVIII-BDD cell cultured media was ana-
lysed by using western blot. A single protein band of ap-
proximately 170 kDa was identified in the media of
cloned cells (Figure 4, lane 1), but not in HEK 293 cells
(Figure 4, lane 2). These data showed that the FVIII-
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lines and secreted into the extracellular media.
To further characterize the function of the recombin-
ant FVIII-BDD protein, the coagulation activity of the
secreted FVIII was measured using a chromogenic assay.
The cloned cells were cultured in 24-well plate, and the
media were changed to serum-free and phenol red ab-
sent DMEM media when the cells reached a confluence
of about 80%. The standard curve of 0-1 IU/mL was pre-
pared using a recombinant coagulation factor VIII
(Bayer, Germany). After cultured for 72 hours, the con-
ditioned media were collected to measure the procoagu-
lant activity of FVIII-BDD and exhibited FVIII-BDD
activity of 14mU/mL.
To determine whether expression of transgene was
stable over time, we maintained HEK 293-FVIII-BDD
cells for 2 months to examine GFP expression by fluor-
escence microscopy. The cell line stably expressed GFP
over 20 passages, and stably expressed FVIII-BDD was
confirmed by qPCR.
Conclusions
In the present study, we used two plasmids containing
AAV ITRs and AAV rep gene to rapidly establish a stable
human cell line with site specific integration of the trans-
gene (FVIII-BDD) at AAVS1 site of human chromosome
19. The single cell cloned HEK 293-FVIII-BDD cell line
consistently and stably expressed FVIII-BDD. Methodo-
logically, we successfully developed a dual plasmids co-
transfection method for the rapid establishment of a
protein expression human cell line with transgene site-
specific integration in human chromosome 19. This
method could be used to easily and quickly produce trans-
gene site-specific integration human cell lines for all other
recombinant protein production.
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